Author's response to reviews

Title: Pharmacological targeting of valosin containing protein (VCP) selectively kills canine lymphoma cells by inducing DNA damage

Authors:

Marie-Eve Nadeau (marie-eve.nadeau@umontreal.ca)
Charlène Rico (chalene.m.rico@gmail.com)
Mayra Tsoi (mayra.tsoi@umontreal.ca)
Mélanie Vivancos (vivancos_melanie@hotmail.fr)
Sabin Filimon (sabin.filimon@umontreal.ca)
Marilène Paquet (marilene.paquet@umontreal.ca)
Derek Boerboom (derek.boerboom@umontreal.ca)

Version: 3
Date: 5 August 2014

Author's response to reviews: see over
St-Hyacinthe, July 31st 2014

Dafne Solera
Executive editor
BMC cancer

Dear Dr Solera,

Please find attached a manuscript entitled "Pharmacological targeting of valosin-containing protein (VCP) selectively kills canine lymphoma cells by inducing DNA damage" by Marie-Eve Nadeau, Charlène Rico, Mayra Tsoi, Mélanie Vivancos, Sabin Filimon, Mariléne Paquet and Derek Boerboom. The authors have all agreed to the submission of the present manuscript and have no competing interests. I also confirm that it is currently not under review by another journal.

This report contains our most recent findings regarding the targeting of valosin-containing protein in the treatment of lymphoma and describes a novel mechanism for cell death induction. We strongly feel that our manuscript will be of great interest to the broad readership of BMC cancer, and would be pleased if you would consider it for publication. We look forward to your response.

Regards,

Marie-Eve Nadeau, DMV, DACVIM (Oncology)
Associate Professor
Département des Sciences Cliniques
Faculté de Médecine Vétérinaire
Université de Montréal
C.P. 5000
St-Hyacinthe (Québec)
Canada J2S 7C6